Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 4/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21836163 | 1.00 | KMT2A (0.46) | KMT2ATLR2PTPN1MDM2 | |
| SCHEMBL26689778 | 1.00 | KMT2A (0.46) | KMT2ATLR2PTPN1MDM2 | |
| SCHEMBL26689395 | 1.00 | KMT2A (0.46) | KMT2ATLR2PTPN1MDM2 | |
| SCHEMBL30678132 | 1.00 | KMT2A (0.46) | KMT2ATLR2PTPN1MDM2 | |
| SCHEMBL26689779 | 1.00 | KMT2A (0.46) | KMT2ATLR2PTPN1MDM2 | |
| SCHEMBL16757551 | 1.00 | KMT2A (0.46) | KMT2ATLR2PTPN1MDM2 | |
| SCHEMBL26689398 | 1.00 | KMT2A (0.46) | KMT2ATLR2PTPN1MDM2 | |
| SCHEMBL29975272 | 1.00 | KMT2A (0.46) | KMT2ATLR2PTPN1MDM2 | |
| SCHEMBL16757654 | 0.93 | TLR2 (0.46) | KMT2ATLR2PTPN1MDM2 | |
| SCHEMBL31557564 | 0.93 | TLR2 (0.46) | KMT2ATLR2PTPN1MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111431-A1 | ANTI-CD7 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | LES LABORATOIRES SERVIER (FR) | 2025-05-30 | — | — | WO | disclosed |
| EP-4525928-A1 | ANTIBODY DRUG CONJUGATES | Novartis AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| EP-4525927-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | Novartis AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| WO-2023223097-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225359-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |